Menu

PCSK9 Drug Reduces Heart Disease Risk

A cholesterol-lowering drug significantly cut the risk of heart attack and stroke in a recent study. But is it worth the steep cost?

Mar 21, 2017
Diana Kwon

Cholesterol buildup in an interlobular arteryFLICKR, BOONYARIT CHEUNSUCHON

An expensive new drug, evolocumab (Repatha), developed by Amgen, significantly drops cholesterol levels and reduced the risk of major cardiovascular events, researchers reported in a study published last week (March 17) in the New England Journal of Medicine.

Evolocumab is a monoclonal antibody that attempts to mimic a mutation in the PCSK9 gene, which can lower the risk of developing heart disease by up to 88 percent. A 2014 placebo-controlled study of 901 patients revealed the evolocumab could reduce low-density lipoprotein (LDL) cholesterol levels by around 60 percent. Clinical trials of alirocumab (Praleunt), a competitor drug developed by Sanofi and Regeneron, have revealed similar effects.

The latest study of evolocumab—a randomized, double-blind, placebo-controlled trial involving more than 27,000 patients—revealed that after two years of treatment, only 9.8 percent of patients experienced a major cardiovascular event, such as a stroke or heart attack, compared to 11.3 percent in the placebo group.

William Hiatt, a physician at the University of Colorado in Denver who was not involved in the study, told Science that that results showed that “a physician would need to treat about 150 patients with Repatha in a year to prevent one of these bad events.” Hiatt added that “the benefit here is meaningful and substantial . . . although not overwhelming.”

Given the modest benefit of this drug, whether it’s worth the $14,523 annual price tag—when statins are a much cheaper alternative, and effective for some patients—remains an open question. While the heart disease risk reduction observed in this latest study was less than what was expected based on initial studies of evolocumab, it still provides an added benefit worth discussing with his patients, Harlan Krumholz, a cardiologist at Yale University who was not involved in the study, told Nature. “It is an exceptionally important study,” he said. “The promise of these drugs has been very clear. Whether they would deliver on that promise was suspected, but not known.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.